Porphyria prevention study halted early – little data to go on
NCT ID NCT02922413
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small phase 2 trial tested whether the drug Panhematin could prevent acute attacks in people with certain types of porphyria. Only 13 participants were enrolled before the study was terminated early. Researchers tracked attacks and serious side effects, but the limited data makes it hard to draw firm conclusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hemin (Panhematin) given intravenously
- What this could lead to
- If it worked, this could point toward a way to prevent painful acute attacks in people with certain porphyrias.
- What could go wrong
- The trial was terminated early and only enrolled 13 people, so results are very limited. It is unclear if Panhematin is truly effective or safe for prevention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE INTERMITTENT PORPHYRIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Medical Branch
Galveston, Texas, 77555, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.